Galleri multi-cancer early detection test
GPTKB entity
Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
cancer screening test
|
| gptkbp:analyzes |
methylation patterns in DNA
|
| gptkbp:clinicalTrialPhase |
gptkb:PATHFINDER_study
|
| gptkbp:detects |
cancer signal origin
multiple types of cancer over 50 types of cancer |
| gptkbp:developedBy |
gptkb:Grail,_Inc.
|
| gptkbp:FDADesignation |
gptkb:Breakthrough_Device_(2021)
|
| gptkbp:headquartersLocation |
gptkb:Menlo_Park,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Galleri multi-cancer early detection test
|
| gptkbp:intendedUse |
early cancer detection
|
| gptkbp:launched |
2021
|
| gptkbp:marketedIn |
gptkb:United_States
|
| gptkbp:method |
blood test
|
| gptkbp:parentCompany |
Illumina (formerly), now independent
|
| gptkbp:prescriptionRequired |
yes
|
| gptkbp:regulates |
not FDA approved (as of 2024)
|
| gptkbp:targetAudience |
adults at elevated risk for cancer
|
| gptkbp:technology |
cell-free DNA analysis
|
| gptkbp:type |
blood
|
| gptkbp:website |
https://www.galleri.com/
|
| gptkbp:bfsParent |
gptkb:Grail,_Inc.
|
| gptkbp:bfsLayer |
6
|